Contribution: Industrial Research Assistance Program – Contributions to Firms
Integrated Nanotherapeutics Inc.
$506,250.00
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in a mouse model of type 1 diabetes
FY 2024-25 · 2024-04-15
Summary
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in non-obese diabetic (NOD) mice, an established mouse model of type 1 diabetes.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
824601991
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2024-04-15 | 2024-25 | $506,250.00 |
| 1 | 2024-04-15 | 2024-25 | $506,250.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 153 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 153 jours.
Agreement End Date
2025-07-31
Agreement Number
1018412
Agreement Start Date
2024-04-15
Agreement Title
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in a mouse model of type 1 diabetes
Agreement Title (French)
Évaluation d’une formulation de nanoparticules lipidiques tolérable pour traiter le diabète de type 1 chez un modèle de souris de diabète de type 1.
Agreement Type
Contribution
Agreement Value
$506,250.00
Amendment Date
2025-02-04
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in non-obese diabetic (NOD) mice, an established mouse model of type 1 diabetes.
Description (French)
Évaluation d’une formulation de nanoparticules lipidiques tolérable pour traiter le diabète de type 1 chez des souris diabétiques non obèses, un modèle de souris établi pour le diabète de type 1.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby South
Federal Riding (French)
Burnaby-Sud
Federal Riding Number
59003
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
824601991
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
Integrated Nanotherapeutics Inc.
Recipient Postal Code
V5G 4X4
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2024-2025-Q1-1018412
